Mitochondrial DNA emerges as a key factor in melanoma checkpoint inhibitor resistance, revealing new potential biomarker for patients.

Company to showcase preclinical studies of ARV-393, an investigational oral PROTAC BCL6 degrader, as a single agent in models ...

Neoadjuvant nivolumab (Opdivo) plus chemotherapy significantly improved overall survival (OS) compared with chemotherapy ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago, IL, was host to a kidney and bladder cancers oral abstract session. Dr. Tian Zhang discussed the ...

Here, we report that Pax3 and Pax7 binding protein 1 (Paxbp1) controls a key checkpoint during this critical transition. Deletion of Paxbp1 in adult MuSCs prevented them from reentering the cell cycle ...

In the present study, we review approaches and studies that have shed some light on cardiomyocyte cell cycle regulation. For reference, an initial description of cardiomyogenic induction and ...

Dato-DXd 6.0 mg/kg was administered intravenously once every 3 weeks on day 1 of each 21-day cycle. The initial dose was infused over ... 3 months of screening were evaluated centrally for tumor cell ...

To address this critical gap, we conducted a comprehensive meta-analysis to assess the prognostic value of SII in NSCLC patients treated with immune checkpoint inhibitors ... (5) Animal and cell-based ...

UNLOXCYT™ (cosibelimab-ipdl) has received FDA approval as the first and only anti-PD-L1 treatment specifically for advanced cutaneous squamous cell carcinoma, establishing Checkpoint as a leader ...

Importantly, it synthesizes recent discoveries regarding resistance mechanisms, including dysregulated cell cycle checkpoints, compensatory signaling pathway activation, and tumor microenvironment ...

School of Life Science and Technology, ShanghaiTech University, Shanghai, China Department of Bioengineering, School of Engineering and Applied Sciences, University of Pennsylvania, Philadelphia, ...